Angiogenic Switch in Patients With Colorectal Cancer

Angiogenic Switch as Predictor of Response to Chemotherapy in Patients With Metastatic Colorectal Cancer

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02075086

Acronym

ANGIOSWITCH

Enrollment

100

Registered

2014-03-03

Start date

2011-07-31

Completion date

2015-05-31

Last updated

2015-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

angiogenic switch, plasma cytokines, Colon cancer

Brief summary

A group of colorectal cancer (CRC) patients treated with chemotherapy and Bevacizumab (Bev) maintain the same sensitivity after progression to maintenance treatment because they remain dependent on VEGF angiogenic mediator, while other patients in whom there is an angiogenic switch (AS) become dependent on other angiogenic cytokines and become resistant to Bev chemotherapy combinations .

Interventions

DRUGXelox or Xeliri Bevacizumab

Chemotherapy treatment

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of stage IV colorectal adenocarcinoma. * Age ≥ 18 years . * Measurable disease by RECIST criteria. * Life expectancy ≥ 6 months. * Candidate to receive treatment with first-line chemotherapy. * Availability of tumor tissue.

Exclusion criteria

* Patients who have received prior treatment with first-line chemotherapy for metastatic disease. * Patients in whom there is contraindication to the administration of either drug used in the study: capecitabine, irinotecan, oxaliplatin or Bev. * Patients receiving anticoagulant oral treatment. * Patient with diagnosis of other malignancies within 5 years prior to diagnosis except basal cell carcinoma or cervical carcinoma · in situ. · The inclusion of patients with malignant disease diagnosed more than 5 years ago without recurrence in the previous 3 years will be analyzed individually * Patients with bone disease as the only manifestation of the disease.

Design outcomes

Primary

Measure	Time frame	Description
Progression Free Survival	1 year	Days from cycle one day one to progression

Secondary

Measure	Time frame	Description
Feasibility	2 years	Feasibility of doing a clinical prospective trial with a measure od plasma citoquines.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026